| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Baylor Genetics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $152M | Series B | 7/1/2026 | $50M | $443.35M | $19.25 | Undisclosed Investors | ||||
 | BlossomHill Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $257.15M | Series B | 2/29/2024 | $184.15M | $400.87M | $17.63 | Colt Ventures, Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules BioVentures Partners, Plaisance Capital Management, H&D Asset Management, Brahma Capital, Primer Ventures | ||||
 | Boundless Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $756.15M | Series C | 5/16/2023 | $100M | $273.76M | $0.70 | Bayer, RA Capital Management, Sectoral Asset Management, Piper Heartland, Healthcare Capital | ||||
 | Capstan Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $152.91M | Series C | 12/11/2024 | $110M | $355.75M | $14.43 | Eclipse, Intuitive Ventures, Yu Galaxy, Gideon Strategic Partners | ||||
 | Convergent Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $130M | Series A-4 | 9/24/2024 | $40M | $269.38M | $2.01 | Novo Holdings | ||||
 | Evozyne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.19M | Series B | 9/27/2023 | $50M | $288.32M | $15.49 | Fidelity Management & Research Company, OrbiMed, NVentures, Paragon Biosciences, Valor Equity Partners | ||||
 | Inceptive Nucleics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $120M | Series A | 9/7/2023 | $100M | $476.75M | $14.24 | NVIDIA, Andreessen Horowitz, Obvious Ventures, S32 | ||||
 | Levita Magnetics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $72.87M | Series D | 4/27/2026 | $30.71M | $311.25M | $0.72 | Aurus Capital, Sprig Equity, Ballast Capital | ||||
 | Quip | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $76.99M | Series C-3 | 1/29/2024 | $2.82M | $190.39M | $2.46 | Undisclosed Investors | ||||
 | Rénibus Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $148.41M | Series B | 7/17/2025 | $90M | $238.38M | $3.06 | Undisclosed Investors | ||||
 | Solera Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $161.62M | Series E-1 | 1/14/2025 | $15M | $173.3M | $1.54 | Health Care Service Corporation, Adams Street, Cobalt Ventures, Horizon Mutual Holdings | ||||
 | Solv Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $95.05M | Series C | 9/2/2021 | $45M | $399.84M | $4.36 | Acrew Capital, Corner Ventures, Greylock Partners, Benchmark Capital | ||||
 | Spinogenix | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $24.4M | Series D | 11/21/2025 | $9.8M | $365.97M | $34.92 | Undisclosed Investors | ||||
 | Tomorrow Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $92.06M | Series B | 6/29/2022 | $60M | $380.93M | $8.96 | BOND, Andreessen Horowitz, Obvious Ventures, BoxGroup, Sound Ventures | ||||
 | Tortugas Neuroscience | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $106M | Series A1 | 4/21/2026 | $33.84M | $273.53M | $7.49 | Cure Ventures, The Column Group, AN Venture Partners | ||||
 | Vedanta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.86M | Series B-1 | 8/6/2026 | $22.57M | $113.87M | $0.17 | AMR Action Fund, BNP Paribas | ||||
 | Aardvark Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $129.13M | Series C | 5/9/2024 | $85M | $267.58M | $1.77 | Decheng Capital, Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Ventures, Silver Arc Private Capital, Prader-Willi Syndrome Association, Vickers Venture Partners, Foundation for Prader-Willi Research | ||||
 | Adaptive Innovations | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $60M | Series A | 6/2/2026 | $50M | $242.97M | $6.26 | Felicis, Optum Ventures, Sunflower Capital, Conviction, BoxGroup, SV Angel, Dorm Room Fund, Constellation, Bain Capital Ventures | ||||
 | Alterome Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $231.07M | Series B | 4/3/2024 | $132M | $356.19M | $4.08 | Goldman Sachs Alternatives, Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, OrbiMed, Nextech Invest, Vida Ventures, Boxer Capital, Colt Ventures | ||||
 | Atavistik | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $260M | Series B-1 | 3/5/2026 | $40M | $422.55M | $1.20 | RA Capital Management | ||||
 | CoRegen | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $131.81M | Series B-1 | 10/28/2025 | $13.5M | $431.58M | $18.00 | Undisclosed Investors | ||||
 | Cresilon | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.82M | Series A-6 | 7/20/2026 | $29M | $247.14M | $0.85 | Undisclosed Investors | ||||
 | Dewpoint | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $354.6M | Series D | 9/10/2025 | $59.12M | $136.62M | $0.23 | 120 Capital | ||||
 | Diagonal Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $253M | Series B | 1/8/2026 | $125M | $447.42M | $2.70 | Sanofi Ventures, Janus Henderson Investors, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management, Woodline Partners, BVF Partners, Atlas Venture, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, Checkpoint Capital, RV Invest, Biovision Ventures | ||||